Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study

Zhou, Bolun; Zang, Ruochuan; Zhang, Moyan; Song, Peng; Liu, Lei; Bie, Fenglong; Peng, Yue; Bai, Guangyu; Gao, Shugeng

doi:10.1016/j.ebiom.2022.103951

Cited by 32 publications

(22 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 In 2020, a total of 2.21 million new cases and 1.80 deaths of lung cancer were estimated globally. 2,3 In the People's Republic of China, because of the massive population, approximately 787,000 new cases of lung cancer were diagnosed in 2015, which has contributed greatly to the disease burden. 4 The major risk factors for lung cancer are smoking, occupational exposure, and air pollution in the People's Republic of China.…”

Section: Introductionmentioning

confidence: 99%

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Zhang

Guo

Zhou

et al. 2022

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Zhang

Guo

Zhou

et al. 2022

Journal of Thoracic Oncology

Self Cite

View full text Add to dashboard Cite

“…Lung cancer is one of the most prevalent cancers and the main cause of cancer-specific deaths globally [ 1 , 2 ]. In 2020, it is anticipated that lung cancer accounts for approximately 1.8 million deaths and 2.2 million new cases worldwide, with the United States accounting for more than ten percent of deaths and new cases [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background The most common form of treatment for non-metastatic lung cancer is surgery-based combination therapy, which may also include adjuvant radiotherapy or chemotherapy. Second primary malignancies (SPMs) are uncommon but significant radiation side effects in patients with resectable lung cancer, and SPMs have not been adequately investigated. Our study aims to assess the correlations of radiotherapy with the development of SPMs in patients with resectable lung cancer. Methods We screened for any primary malignancy that occurred more than five years after the diagnosis of resectable lung cancer. Based on the large cohort of the Surveillance, Epidemiology and End Results database, radiotherapy-correlated risks were estimated using the Poisson regression analysis and the cumulative incidence of SPMs was calculated using Fine-Gray competing risk regression analysis. Results Among the 62,435 patients with non-metastatic lung cancer undergoing surgery, a total of 11,341 (18.16%) patients have received radiotherapy. Our findings indicated that radiotherapy was substantially related to a high risk of main second solid malignancies (RR = 1.21; 95%CI, 1.08 to 1.35) and a negligible risk of main second hematologic malignancies (RR = 1.08; 95%CI, 0.84 to 1.37). With the greatest number of patients, the risk of acquiring a second primary gastrointestinal cancer was the highest overall (RR = 1.77; 95 percent CI, 1.44 to 2.15). The cumulative incidence and standardized incidence ratios of SPMs revealed similar findings. Furthermore, the young and the elderly may be more vulnerable, and the highest risk of acquiring most SPMs was seen more than ten years after lung cancer diagnosis. Additionally, more attention should be paid to the second primary gastrointestinal cancer in young individuals with resectable lung cancer. Conclusion After receiving radiotherapy, an increased risk of developing second primary solid and gastrointestinal cancers was observed for patients with resectable lung cancer. The prevention of SPMs associated with radiotherapy requires further attention.

show abstract

“…Lung cancer is one of the most fatal and widespread cancers worldwide, with non-small cell lung cancer (NSCLC) accounting for around eighty percent of all occurrences. 1 , 2 Previously published research revealed that the accumulation of genetic mutations, such as EGFR, KRAS, and ALK, contributed to the development of NSCLC. 3 Apart from these, epigenetic alterations in certain genes may also contribute to the progression of NSCLC.…”

Section: Introductionmentioning

confidence: 99%

RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer

Zhou¹,

Bie²,

Zang³

et al. 2022

eBioMedicine

Self Cite

View full text Add to dashboard Cite

Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study

Cited by 32 publications

References 30 publications

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Association between radiotherapy and risk of second primary malignancies in patients with resectable lung cancer: a population-based study

RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer

Contact Info

Product

Resources

About